Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M266Revenue $M42.5Net Margin (%)-118.4Altman Z-Score-1.9
Enterprise Value $M120EPS $-0.4Operating Margin %-105.4Piotroski F-Score6
P/E(ttm)--Beneish M-Score-4.7Pre-tax Margin (%)-118.4Higher ROA y-yY
Price/Book5.810-y EBITDA Growth Rate %-26.9Quick Ratio6.8Cash flow > EarningsY
Price/Sales5.35-y EBITDA Growth Rate %-23.2Current Ratio7.1Lower Leverage y-yY
Price/Free Cash Flow3.5y-y EBITDA Growth Rate %--ROA % (ttm)-24.9Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-268.9Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M145ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with OREX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
OREXSeth Klarman 2015-09-30 Buy 0.03%$2.04 - $4.93
($3.44)
$ 1.84-47%New holding821,363
OREXGeorge Soros 2012-06-30 Sold Out -0.03%$3.16 - $6.37
($3.76)
$ 1.84-51%Sold Out0
OREXGeorge Soros 2012-03-31 Buy 0.03%$1.68 - $5.01
($3.11)
$ 1.84-41%New holding500,000
OREXFirst Eagle Investment 2010-09-30 Sold Out -0.01%$3.9 - $6.77
($4.98)
$ 1.84-63%Sold Out0
OREXFirst Eagle Investment 2010-06-30 Add$4.05 - $7.04
($5.57)
$ 1.84-67%Add 74.07%470,000
OREXFirst Eagle Investment 2010-03-31 Add$5.9 - $7.66
($6.55)
$ 1.84-72%Add 22.73%270,000
OREXFirst Eagle Investment 2009-12-31 Add0.01%$6.44 - $9.39
($7.57)
$ 1.84-76%Add 83.33%220,000
OREXFirst Eagle Investment 2009-09-30 Buy 0.01%$5.2 - $10.34
($7.89)
$ 1.84-77%New holding120,000
OREXBill Gates 2009-06-30 Sold Out $1.89 - $5.21
($3.19)
$ 1.84-42%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

OREX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


OREX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Booth Mark DChief Commercial Officer 2015-02-26Sell50,000$5.68-67.61view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-12-02Sell22,643$6-69.33view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-11-25Sell31,388$5.83-68.44view
BOCK LOUIS CDirector 2014-11-18Buy1,325$5.58-67.03view
BOCK LOUIS CDirector 2014-11-12Buy27,052$5.57-66.97view
Turner Heather DVP, Gen. Counsel & Secretary 2014-09-22Sell300,000$4.47-58.84view
NARACHI MICHAELPresident and CEO 2014-09-15Buy50,000$4.78-61.51view
Hagan Joseph PSr. VP, Corporate Development 2014-09-15Buy5,000$4.69-60.77view
Hagan Joseph PChief Business Officer 2013-07-31Sell12,000$7.8-76.41view
Booth Mark DChief Commercial Officer 2013-07-26Sell64,767$7.55-75.63view

Quarterly/Annual Reports about OREX:

News about OREX:

Articles On GuruFocus.com
Value Investing in BioPharma Nov 18 2015 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
Oxford Industries (OXM) Solid Growth Metrics, Orexigen Therapeutics (OREX) European Anti-Obesity App Mar 27 2015 
Orexigen Therapeutics' Bright Future Mar 03 2015 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby Corporation, an Jul 15 2012 
Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples Inc, and Orexigen Therap Jul 08 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 

More From Other Websites
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure Feb 04 2016
Orexigen Therapeutics to Speak at Upcoming Investor Conferences Feb 02 2016
8 Stocks Under $10 Making Big Moves Higher Jan 22 2016
Orexigen Targets Profitability by 2018, Focus on Contrave Jan 12 2016
Orexigen announces 2016 financial outlook and key priorities Jan 11 2016
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 11 2016
Orexigen announces 2016 financial outlook and key priorities Jan 11 2016
Orexigen Therapeutics names Thomas Lynch as EVP, General Counsel & Secretary and Heather Ace as EVP,... Jan 08 2016
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jan 08 2016
Orexigen Therapeutics names Thomas Lynch as EVP, General Counsel & Secretary and Heather Ace as EVP,... Jan 08 2016
Orexigen Therapeutics to Speak at the J.P. Morgan 2016 Global Healthcare Conference Jan 05 2016
Orexigen Therapeutics to Speak at the J.P. Morgan 2016 Global Healthcare Conference Jan 05 2016
10 Biotechs Short Sellers Are Betting Against Dec 29 2015
Orexigen Therapeutics, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 22 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK